Email Updates

You are here

Home

12 MARCH 2021 VOLUME 23 ISSUE 10

Media Coverage

  • Major Conference on HIV and COVID-19 Under Fire for Putting Science Behind Paywall

    In the shut-down world of COVID-19, medical science conferences take place virtually—and protests do, too. Such was the case this week during the Conference on Retroviruses and Opportunistic Infections (CROI 2021), which from March 6 to March 10 featured breaking, clinically important research on HIV and the novel coronavirus.

    March 11, 2021
    General
    The BodyPro

  • Therapeutic HIV Vax Trial Takes Its First-in-Human Steps — But long way from a true functional cure

    A therapeutic HIVACAT T-cell immunogen (HTI) vaccine regimen was safe, and about 40 percent of recipients were able to stay off antiretroviral therapy (ART) for several months, a researcher said.

    March 11, 2021
    Therapeutic Vaccines, Treatment
    MedPage Today

  • Young Women Face Scorn From Their Families Over Use of PrEP

    Ordinarily, family members and romantic partners are the pillars of support when someone enters uncharted waters or takes a big life decision. But a new study among teenage girls and young women who take HIV pre-exposure prophylaxis (PrEP) suggests this is not always the case.

    March 11, 2021
    PrEP
    Times Live

  • Lenacapavir Linked to Significant Drop in Viral Load in Multidrug Resistant HIV

    A twice-yearly shot of the investigational antiretroviral medicine lenacapavir (Gilead Sciences) was associated with nearly a two-log drop in HIV viral load when paired with an optimized backbone antiretroviral regimen in people with resistance to multiple drug classes and few fully active treatment options.

    March 11, 2021
    Treatment
    Medscape

  • Social Networks Key to PrEP Uptake in Rural Kenya and Uganda

    Those at an elevated risk of HIV exposure were 57 percent more likely to start PrEP if they had a social network contact who had already started using PrEP in rural Kenya and Uganda, Dr Catherine Koss from the University of California, San Francisco told the virtual Conference on Retroviruses and Opportunistic Infections 2021 this week.

    March 11, 2021
    PrEP
    aidsmap

  • mRNA Vaccine Protects Monkeys Against HIV-Like Virus

    The same messenger RNA (mRNA) approach used for the highly effective Pfizer-BioNTech and Moderna COVID-19 vaccines also shows promise for protection against HIV, according to a presentation this week at the virtual Conference on Retroviruses and Opportunistic Infections.

    March 11, 2021
    HIV Vaccine
    aidsmap

  • Clinicians Seldom Refer Black Partners of People With HIV for PrEP

    Public health workers in the South were 75 percent less likely than those in the Northeast to refer Black people in relationships with people with HIV for pre-exposure prophylaxis (PrEP), according to data presented at the Conference on Retroviruses and Opportunistic Infections.

    March 10, 2021
    PrEP
    POZ

  • Islatravir PrEP Implant Could Prevent HIV for a Year

    An experimental islatravir implant that can be replaced just once a year could one day be a convenient new option for HIV pre-exposure prophylaxis (PrEP), according to early study results presented this week at the virtual Conference on Retroviruses and Opportunistic Infections (CROI).

    March 10, 2021
    PrEP
    POZ

  • Vaginal Ring May Shield Women From HIV for Three Months at a Time

    A vaginal ring that slowly releases an antiviral medication could protect women against HIV for up to three months, a preliminary trial suggests. It assessed two formulations of a vaginal ring that releases the antiretroviral dapivirine in the vagina over the course of 90 days.

    March 10, 2021
    Microbicides
    UPI

  • Do HIV Drug Trials Need Better Infection Tests? — Data from PrEP study reveal a sensitivity problem

    An extended testing protocol helped reclassify incident HIV infections as baseline infections in a randomized trial involving patients using long-acting cabotegravir as injectable pre-exposure prophylaxis (PrEP), a researcher said.

    March 10, 2021
    General, PrEP
    MedPage Today

  • Achilles’ Heel Spotted for Promising HIV Prevention Drug

    Researchers revisited a 4,570-person clinical trial of the drug, examining blood samples collected during the study, and found that four people who contracted HIV despite receiving injections of the medication, called cabotegravir, had been infected for more than a month before ordinary HIV tests detected the virus. During this time, they developed resistance to cabotegravir and closely-related therapies that are used to treat HIV infections. Although alternatives to these common drugs can treat HIV infections, they can be expensive or difficult to obtain in some countries.

    March 9, 2021
    PrEP
    Nature

  • Large Numbers Now on Descovy PrEP in the United States

    In the year following the US approval of emtricitabine/TAF (Descovy) as PrEP in October 2019, 29 percent of existing PrEP users switched to the newer formulation and 36 percent of new PrEP users started on it. Dr. Karen Hoover of the Centers for Disease Control and Prevention presented these data, based on a large pharmacy database, to the virtual Conference on Retroviruses and Opportunistic Infections (CROI 2021) this week.

    March 9, 2021
    PrEP
    aidsmap

  • The Next Generation of HIV Drugs Is Looking Really Promising

    The next generation of medications and preventative treatments for HIV/AIDS continues to look promising. New research released Tuesday suggests that people can safely wear a vaginal ring-based treatment meant to prevent HIV infection for as long as three months. A monthly version of the same drug is already being weighed for approval in African countries and elsewhere.

    March 9, 2021
    Microbicides, PrEP, Treatment
    Gizmodo

  • As HIV Outbreak Grips WV, Electeds Move to Cripple Syringe Programs

    At the same moment HIV cases linked to injection drug use are spiking dangerously in West Virginia, state lawmakers have made it much harder to operate syringe service programs (SSP). This comes amid a years-long movement throughout the state to restrict or outright ban SSP, which have been proven to save lives and reduce infectious disease.

    March 8, 2021
    General
    Filter

Published Research

Announcements